Particle Number vs. Cholesterol Mass: The Emerging Role of ApoB in Refining Cardiovascular Risk Stratification

Sofia-Panagiota Giannakopoulou

doi:10.53941/ijctm.2026.100006

Abstract

Cardiovascular diseases (CVDs) remain the leading cause of global mortality and disease burden, with a growing cohort of patients presenting with acute coronary syndrome despite lacking standard modifiable risk factors. This persistent residual risk dictates a shift toward more accurate biomarkers. Historically, lipid management has centered on LDL-C, a measure of cholesterol mass. However, LDL-C fails to account for particle heterogeneity, which is critical since the number of atherogenic apolipoprotein-B (apoB) containing particles, not their cholesterol mass, seems to drive plaque retention. This mini review scopes the contemporary evidence supporting the utility of apoB as a superior metric for risk stratification and therapeutic targeting. Evidence from Mendelian Randomization (MR) studies suggests a causal association between apoB and CVD risk. Furthermore, both observational and discordance analyses demonstrate that apoB, by representing a direct count of all circulating atherogenic particles, is a more accurate predictor of CVD risk than traditional markers like LDL-C and non-HDL-C, suggesting its superiority for identifying high-risk individuals. Despite its established analytical advantages, apoB testing remains vastly underutilized in routine clinical practice, often downgraded to a secondary status in global guidelines. Implementation is significantly hampered by the lack of universal assay harmonization and historical health insurance payment policies that categorize the test as optional. As evidence increasingly identifies apoB as a superior predictor of cardiovascular risk compared to LDL-C and non-HDL-C, its adoption as a high-value alternative target warrants serious consideration.

References

1.
GBD 2023 Cardiovascular Disease Collaborators. Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990–2023. J. Am. Coll. Cardiol. 2025, 86, 2167–2243. https://doi.org/10.1016/j.jacc.2025.08.015.
2.
Kong, G.; Chin, Y.H.; Chong, B.; et al. Higher Mortality in Acute Coronary Syndrome Patients Without Standard Modifiable Risk Factors: Results from a Global Meta-Analysis of 1,285,722 Patients. Int. J. Cardiol. 2023, 371, 432–440. https://doi.org/10.1016/j.ijcard.2022.09.062.
3.
Borén, J.; Williams, K.J. The Central Role of Arterial Retention of Cholesterol-Rich Apolipoprotein-B-Containing Lipoproteins in the Pathogenesis of Atherosclerosis: A Triumph of Simplicity. Curr. Opin. Lipidol. 2016, 27, 473–483. https://doi.org/10.1097/MOL.0000000000000330.
4.
De Oliveira-Gomes, D.; Joshi, P.H.; Peterson, E.D.; et al. Apolipoprotein B: Bridging the Gap Between Evidence and Clinical Practice. Circulation 2024, 150, 62–79. https://doi.org/10.1161/CIRCULATIONAHA.124.068885.
5.
Öörni, K.; Lorey, M.B. Beyond Cholesterol: Linking the Conformation of Apolipoprotein B to Atherogenesis. Curr. Opin. Lipidol. 2025, 36, 226–231. https://doi.org/10.1097/MOL.0000000000000997.
6.
Jackson, E.J.; Willard, K.E.; Ballantyne, C.M. LDL Cholesterol Management Simplified in Adults-Lower for Longer Is Better: Guidance from the National Lipid Association. J. Clin. Lipidol. 2025, 19, 1200–1207. https://doi.org/10.1016/j.jacl.2025.06.002.
7.
Mach, F.; Koskinas, K.C.; Roeters van Lennep, J.E.; et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur. Heart J. 2025, 46, 4359–4378. https://doi.org/10.1093/eurheartj/ehaf190.
8.
Sehayek, D.; Cole, J.; Björnson, E.; et al. ApoB, LDL-C, and Non-HDL-C as Markers of Cardiovascular Risk. J. Clin. Lipidol. 2025, 19, 844–859. https://doi.org/10.1016/j.jacl.2025.05.024.
9.
Mach, F.; Baigent, C.; Catapano, A.L.; et al. 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk. Eur. Heart J. 2020, 41, 111–188. https://doi.org/10.1093/eurheartj/ehz455.
10.
Diffenderfer, M.R.; Schaefer, E.J. The Composition and Metabolism of Large and Small LDL. Curr. Opin. Lipidol. 2014, 25, 221–226. https://doi.org/10.1097/MOL.0000000000000067.
11.
Otvos, J.D.; Mora, S.; Shalaurova, I.; et al. Clinical Implications of Discordance Between Low-Density Lipoprotein Cholesterol and Particle Number. J. Clin. Lipidol. 2011, 5, 105–113. https://doi.org/10.1016/j.jacl.2011.02.001.
12.
Ivanova, E.A.; Myasoedova, V.A.; Melnichenko, A.A.; et al. Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases. Oxid. Med. Cell. Longev. 2017, 2017, 1273042. https://doi.org/10.1155/2017/1273042.
13.
Superko, H.R.; Gadesam, R.R. Is It LDL Particle Size or Number That Correlates with Risk for Cardiovascular Disease? Curr. Atheroscler. Rep. 2008, 10, 377–385. https://doi.org/10.1007/s11883-008-0059-2.
14.
Fernández-Friera, L.; Fuster, V.; López-Melgar, B.; et al. Normal LDL-Cholesterol Levels Are Associated with Subclinical Atherosclerosis in the Absence of Risk Factors. J. Am. Coll. Cardiol. 2017, 70, 2979–2991. https://doi.org/10.1016/j.jacc.2017.10.024.
15.
Sniderman, A.D.; Thanassoulis, G.; Glavinovic, T.; et al. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiol. 2019, 4, 1287–1295. https://doi.org/10.1001/jamacardio.2019.3780.
16.
Borén, J.; Packard, C.J.; Binder, C.J. Apolipoprotein B-Containing Lipoproteins in Atherogenesis. Nat. Rev. Cardiol. 2025, 22, 399–413. https://doi.org/10.1038/s41569-024-01111-0.
17.
Rehman, M.B.; Björnson, E.; Adiels, M.; et al. Risk-Weighted ApoB: A Novel Summary Metric Outperforming Traditional Lipid Biomarkers in Predicting Coronary Heart Disease. Eur. Heart J. 2026, ehaf1124. https://doi.org/10.1093/eurheartj/ehaf1124.
18.
Richardson, T.G.; Sanderson, E.; Palmer, T.M.; et al. Evaluating the Relationship Between Circulating Lipoprotein Lipids and Apolipoproteins with Risk of Coronary Heart Disease: A Multivariable Mendelian Randomisation Analysis. PLoS Med. 2020, 17, e1003062. https://doi.org/10.1371/journal.pmed.1003062.
19.
Zuber, V.; Gill, D.; Ala-Korpela, M.; et al. High-Throughput Multivariable Mendelian Randomization Analysis Prioritizes Apolipoprotein B as Key Lipid Risk Factor for Coronary Artery Disease. Int. J. Epidemiol. 2021, 50, 893–901. https://doi.org/10.1093/ije/dyaa216.
20.
Ference, B.A.; Kastelein, J.J.P.; Ginsberg, H.N.; et al. Association of Genetic Variants Related to CETP Inhibitors and Statins with Lipoprotein Levels and Cardiovascular Risk. JAMA 2017, 318, 947–956. https://doi.org/10.1001/jama.2017.11467.
21.
Khan, S.U.; Khan, M.U.; Valavoor, S.; et al. Association of Lowering Apolipoprotein B with Cardiovascular Outcomes Across Various Lipid-Lowering Therapies: Systematic Review and Meta-Analysis of Trials. Eur. J. Prev. Cardiol. 2020, 27, 1255–1268. https://doi.org/10.1177/2047487319871733.
22.
Ference, B.A.; Kastelein, J.J.P.; Catapano, A.L. Lipids and Lipoproteins in 2020. JAMA 2020, 324, 595–596. https://doi.org/10.1001/jama.2020.5685.
23.
Richardson, T.G.; Wang, Q.; Sanderson, E.; et al. Effects of Apolipoprotein B on Lifespan and Risks of Major Diseases Including Type 2 Diabetes: A Mendelian Randomisation Analysis Using Outcomes in First-Degree Relatives. Lancet Healthy Longev. 2021, 2, e317–e326. https://doi.org/10.1016/S2666-7568(21)00086-6.
24.
Thanassoulis, G.; Williams, K.; Ye, K.; et al. Relations of Change in Plasma Levels of LDL-C, Non-HDL-C and ApoB with Risk Reduction from Statin Therapy: A Meta-Analysis of Randomized Trials. J. Am. Heart Assoc. 2014, 3, e000759. https://doi.org/10.1161/JAHA.113.000759.
25.
Robinson, J.G.; Wang, S.; Jacobson, T.A. Meta-Analysis of Comparison of Effectiveness of Lowering Apolipoprotein B Versus Low-Density Lipoprotein Cholesterol and Nonhigh-Density Lipoprotein Cholesterol for Cardiovascular Risk Reduction in Randomized Trials. Am. J. Cardiol. 2012, 110, 1468–1476. https://doi.org/10.1016/j.amjcard.2012.07.007.
26.
Sniderman, A.; McQueen, M.; Contois, J.; et al. Why Is Non-High-Density Lipoprotein Cholesterol a Better Marker of the Risk of Vascular Disease Than Low-Density Lipoprotein Cholesterol? J. Clin. Lipidol. 2010, 4, 152–155. https://doi.org/10.1016/j.jacl.2010.03.005.
27.
Sniderman, A.D.; Williams, K.; Contois, J.H.; et al. A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk. Circ. Cardiovasc. Qual. Outcomes 2011, 4, 337–345. https://doi.org/10.1161/CIRCOUTCOMES.110.959247.
28.
Emerging Risk Factors Collaboration; Di Angelantonio, E.; Sarwar, N.; et al. Major Lipids, Apolipoproteins, and Risk of Vascular Disease. JAMA 2009, 302, 1993–2000. https://doi.org/10.1001/jama.2009.1619.
29.
Boekholdt, S.M.; Arsenault, B.J.; Mora, S.; et al. Association of LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B Levels with Risk of Cardiovascular Events Among Patients Treated with Statins: A Meta-Analysis. JAMA 2012, 307, 1302–1309. https://doi.org/10.1001/jama.2012.366.
30.
Sondermeijer, B.M.; Rana, J.S.; Arsenault, B.J.; et al. Non-HDL Cholesterol vs. Apo B for Risk of Coronary Heart Disease in Healthy Individuals: The EPIC-Norfolk Prospective Population Study. Eur. J. Clin. Invest. 2013, 43, 1009–1015. https://doi.org/10.1111/eci.12129.
31.
Su, X.; Wang, M.; Zuo, Y.; et al. Apolipoprotein Particle and Cardiovascular Risk Prediction (from a Prospective Cohort Study). Am. J. Cardiol. 2023, 201, 34–41. https://doi.org/10.1016/j.amjcard.2023.05.052.
32.
Emerging Risk Factors Collaboration; Di Angelantonio, E.; Gao, P.; et al. Lipid-Related Markers and Cardiovascular Disease Prediction. JAMA 2012, 307, 2499–2506. https://doi.org/10.1001/jama.2012.6571.
33.
Welsh, C.; Celis-Morales, C.A.; Brown, R.; et al. Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease. Circulation 2019, 140, 542–552. https://doi.org/10.1161/CIRCULATIONAHA.119.041149.
34.
Wong, W.K.; Takeuchi, F.; Thao, L.T.P.; et al. Integration of Apolipoprotein B into the SCORE2 Framework: Implications for Cardiovascular Risk Prediction. Eur. J. Prev. Cardiol. 2025, 32, 575–584. https://doi.org/10.1093/eurjpc/zwaf039.
35.
Sniderman, A.D.; Pencina, M.; Thanassoulis, G. Limitations in the Conventional Assessment of the Incremental Value of Predictors of Cardiovascular Risk. Curr. Opin. Lipidol. 2015, 26, 210–214. https://doi.org/10.1097/MOL.0000000000000181.
36.
Johannesen, C.D.L.; Mortensen, M.B.; Nordestgaard, B.G.; et al. Discordance Analyses Comparing LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B for Cardiovascular Risk Estimation. Atherosclerosis 2025, 403, 119139. https://doi.org/10.1016/j.atherosclerosis.2025.119139.
37.
Peng, A.W.; Gianos, E.; Shapiro, M.D.; et al. Prevalence of Apolipoprotein B and LDL-Cholesterol Discordance: Insights from the Very Large Database of Lipids (VLDbL) and the National Health and Nutrition Examination Survey (NHANES). Circulation 2025, 153, 4. https://doi.org/10.1161/CIRCULATIONAHA.125.077998.
38.
Visseren, F.L.J.; Mach, F.; Smulders, Y.M.; et al. 2021 ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice. Eur. Heart J. 2021, 42, 3227–3337. https://doi.org/10.1093/eurheartj/ehab484.
39.
Arnett, D.K.; Blumenthal, R.S.; Albert, M.A.; et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 2019, 74, e177–e232. https://doi.org/10.1016/j.jacc.2019.03.010.
40.
Sayed, A.; Peterson, E.D.; Virani, S.S.; et al. Individual Variation in the Distribution of Apolipoprotein B Levels Across the Spectrum of LDL-C or Non-HDL-C Levels. JAMA Cardiol. 2024, 9, 741–747. https://doi.org/10.1001/jamacardio.2024.1310.
41.
Remaley, A.T.; Cole, J.; Sniderman, A.D. ApoB Is Ready for Prime Time. J. Am. Coll. Cardiol. 2024, 83, 2274–2275. https://doi.org/10.1016/j.jacc.2024.04.008.
42.
Kohli-Lynch, C.N.; Thanassoulis, G.; Moran, A.E.; et al. The Clinical Utility of ApoB Versus LDL-C/Non-HDL-C. Clin. Chim. Acta 2020, 508, 103–108. https://doi.org/10.1016/j.cca.2020.05.001.
43.
Langlois, M.R.; Sniderman, A.D. Non-HDL Cholesterol or ApoB: Which to Prefer as a Target for the Prevention of Atherosclerotic Cardiovascular Disease? Curr. Cardiol. Rep. 2020, 22, 67. https://doi.org/10.1007/s11886-020-01323-z.
44.
Soffer, D.E.; Marston, N.A.; Maki, K.C.; et al. Role of Apolipoprotein B in the Clinical Management of Cardiovascular Risk in Adults: An Expert Clinical Consensus from the National Lipid Association. J. Clin. Lipidol. 2024, 18, e647–e663. https://doi.org/10.1016/j.jacl.2024.08.013.
45.
Paquette, M.; Bernard, S.; Blank, D.; et al. A Simplified Diagnosis Algorithm for Dysbetalipoproteinemia. J. Clin. Lipidol. 2020, 14, 431–437. https://doi.org/10.1016/j.jacl.2020.06.004.
46.
Rehman, M.B.; Tudrej, B.V. Lipoprotein (a) and Risk-Weighted Apolipoprotein B: A Novel Metric for Atherogenic Risk. Lipids Health Dis. 2024, 23, 316. https://doi.org/10.1186/s12944-024-02307-6.
47.
Kalra, D.K.; Shotwell, M.; Garg, A.; et al. Lipoprotein X—Pathophysiology, Diagnosis, and Management. J. Clin. Lipidol. 2025, 19, 759–774. https://doi.org/10.1016/j.jacl.2025.05.015.
48.
Murdock, D.J.; Moll, K.; Sanchez, R.J.; et al. Low Prevalence of Testing for Apolipoprotein B and Lipoprotein(a) in the Real World. Am. J. Prev. Cardiol. 2024, 19, 100721. https://doi.org/10.1016/j.ajpc.2024.100721.
49.
Contois, J.H.; Delatour, V. Apolipoprotein B Measurement: Need for Standardization. J. Clin. Lipidol. 2018, 12, 264–265. https://doi.org/10.1016/j.jacl.2018.02.017.
50.
Cao, J.; Steffen, B.T.; Guan, W.; et al. A Comparison of Three Apolipoprotein B Methods and Their Associations with Incident Coronary Heart Disease Risk over a 12-Year Follow-Up Period: The Multi-Ethnic Study of Atherosclerosis. J. Clin. Lipidol. 2018, 12, 300–304. https://doi.org/10.1016/j.jacl.2017.12.013.
51.
Langlois, M.R. Investigations on the Clinical Utility of Apolipoprotein B Measurement: A Research Priority. Eur. J. Prev. Cardiol. 2020, 27, 1252–1254. https://doi.org/10.1177/2047487319869578.
52.
Nordestgaard, B.G.; Langlois, M.R.; Langsted, A.; et al. Quantifying Atherogenic Lipoproteins for Lipid-Lowering Strategies: Consensus-Based Recommendations from EAS and EFLM. Atherosclerosis 2020, 294, 46–61. https://doi.org/10.1016/j.atherosclerosis.2019.12.005.
53.
Galimberti, F.; Casula, M.; Olmastroni, E. Apolipoprotein B Compared with Low-Density Lipoprotein Cholesterol in the Atherosclerotic Cardiovascular Diseases Risk Assessment. Pharmacol. Res. 2023, 195, 106873. https://doi.org/10.1016/j.phrs.2023.106873.
54.
Cole, J.; Otvos, J.D.; Remaley, A.T. A Translational Tool to Facilitate Use of Apolipoprotein B for Clinical Decision-Making. Clin. Chem. 2023, 69, 41–47. https://doi.org/10.1093/clinchem/hvac161.
55.
Garcia, E.; Bennett, D.W.; Connelly, M.A.; et al. The Extended Lipid Panel Assay: A Clinically-Deployed High-Throughput Nuclear Magnetic Resonance Method for the Simultaneous Measurement of Lipids and Apolipoprotein B. Lipids Health Dis. 2020, 19, 247. https://doi.org/10.1186/s12944-020-01424-2.
56.
Wolska, A.; Lloyd-Jones, D.M.; Remaley, A.T. Measure Apolipoprotein B If We Believe What We Say About Precision Medicine. Circulation 2025, 151, 257–259. https://doi.org/10.1161/CIRCULATIONAHA.123.067559.

Scilight Press

Author Information

Abstract

Keywords

References

About Scilight

Journals

Publishing Policies

Contact Us